AquaHeart: Revolutionizing Atrial Fibrillation Treatment with Groundbreaking Technology

Welcome to AquaHeart, the trailblazing MedTech startup at the forefront of medical innovation. We are proud to introduce our state-of-the-art single-shot Pulmonary Vein Isolation therapy, designed to transform the way we address atrial fibrillation. With a relentless commitment to excellence and a team of world-class experts, we are revolutionizing the field of cardiovascular solutions.

Recognized as a Top 10 Cardiovascular Solution Provider

April 2023, AquaHeart was honored to be listed as a top 10 solution provider in the cardiovascular space. Our CEO, Dr. Holger Friedrich, highlighted the remarkable benefits of the AquaHeart system in an article, solidifying our position as leaders in the field of Pulmonary Vein Isolation. We are proud to be driving advancements that will reshape the landscape of cardiac care.

Award for Top 10 Cardio Vascular Solution Provider 2023 from MEDTECH OUTLOOK

Read the full article HERE

Atrial Fibrillation leads to stroke

By the time a human reaches age 65 its heart will have beaten over two billion times. This enormous performance wears on the heart muscle. It is estimated that for up to 15% of humans this strain can result in Atrial Fibrillation, leading to a higher risk of stroke.

Today´s treatment is only for 
the 10%

Current market studies estimate that roughly 1 million heart ablations are performed every year, comparing this to a global population of 700 million people above the age of 65. 

So current technologies do not scale to the needed level.

Democratizing Heart Ablation

As only 10% of the treatable population in need are treated, we made it our mission to develop a technology that can be applied faster, safer, and more easily, so that we can address the huge majority currently not served. The “over the wire” technique allows for fast and safe single shot Pulmonary Vein insulation.

Based on proven Aqua technology

The Aqua Group of companies have developed a technology platform consisting of multiple patent families and medical devices of which the first have passed FDA approval and are in First-In-Human (FIH) stage.

Developed by leading cardiologist

Aqua Heart works with global leading experts in the field of Heart Ablations as well as medical device engineers to build a globally applicable, safe and easy to use, single-shot-high-energy heart ablation system.

In advanced stage

Aqua Heart was founded in 2018 based on already successful developments of other companies in the Aqua Group.

Aqua Heart´s medical device is in advanced stage of development and regulatory approval.

Democratizing Heart Ablation for a Larger Population

Atrial Fibrillation is a potentially deadly condition, yet only 10% of patients receive curative treatment today. At AquaHeart, we are on a mission to change that. Our groundbreaking high-energy, short-duration, single-shot Pulmonary Vein Isolation technology is paving the way for accessible treatment on a global scale.

By developing a solution that can be applied faster, safer, and more easily, we are addressing a large unmet need of untreated Atrial Fibrillation patients. With AquaHeart, heart ablation is no longer limited to a select few—it is now within reach for all patients and interventional cardiologist.

How we achieve democratization

More cardiologist can perform Heart Ablations with Aqua Heart´s technology

Heart Ablations today need the highest skilled electro-physiologist cardiologists with large supporting teams in their catheter laboratories.

Aqua Heart´s technology is developed in a way that complicated mapping procedures are not required, and the system provides real time success feedback. 

The safe and simple technology can be applied in much more hospitals

Electro physiology catheter laboratories are only available in highly specialized clinics due to their cost and complexity.

Aqua Heart´s technology uses a strictly anatomical approach, which reduces several of the traditional preconditions to provide ablative Atrial Fibrillation therapy. 

Our Team

Our team of world leading cardio and medical engineering experts

Dr. Holger Friedrich 
CEO, (MD, PhD)

Serial entrepreneur with 30+years experience in medical devices, esp. Cardiovascular,
ex St. Jude, ex Ventritex

Greg Wilson

Consulting CFO to >50 early-stage life sciences companies. MBA/CPA

Eric Fain, MD

President and CEO of Procyrion inc., Houston
Former Group President, St. Jude Medical/Abbott

Kevin Holbrook, 

VP Engineering

Positions at AVE, Medtronic, Synecor, Innerpulse, Creganna Medical. Long term catheter development expertise

Andrea Biffi


Sole director and Chief Executive Officer of Three Heads Investment S.r.l.: Former CEO and Director at  Sofar S.p.A. (“Sofar”). President and board member of 1LAB SA. Sole director of BLL Invest srl. Member of the Board of Asensus Surgical, inc. (NYSE).

Philip Ebeling, 

Head of the Engineering Advisory Board

COO of Inspire inc. former CTO St. Jude/Abbott

Venkatakrishna Tholakanahalli, MD, FHRS

Consulting Medical Director

Cardiologist in Minneapolis, Minnesota and is affiliated with Minneapolis Veterans Affairs Health Care System. He received his medical degree from Bangalore Medical College and has been in practice for more than 20 years.
Expert and scientific researcher in EP, especially ventricular ablation programs

Virender K Sharma, 


Founder, Inventor, Serial Entrepreneur, Doctor of Gastroenterology, former Professor at Mayo Clinic

Dr. VK Sharma is a practicing gastroenterologist and a serial entrepreneur with 20+ years of experience. He held the positions of Professor of Medicine at the Mayo Clinic School of Medicine and Vice-Chair of Gastroenterology Research, making significant contributions to the field.

Dr. Sharma has founded multiple successful MedTech device startups in gastrointestinal endoscopy, surgery, cardiology, Women's Health, and Consumer Health. These ventures have secured over $100 million in venture funding, showcasing confidence in his innovative ideas.

With a strong focus on innovation, Dr. Sharma possesses an impressive portfolio of 100+ issued US and international patents. His contributions to medical science include 300+ peer-reviewed articles, book chapters, research abstracts, and presentations. He has been recognized by Stanford University, being listed among the world's top 2% of scientists.

Dr. Sharma's achievements have garnered him recognition and fellowship in esteemed organizations such as the American Gastroenterological Association, the American College of Gastroenterology, and the American Society for Gastrointestinal Endoscopy. Through his expertise and entrepreneurial drive, he continues to shape the future of gastroenterology and healthcare

Companies (Co-)Founded

2020 - present

Founder, Chairman, CEO, Libero Health Inc.

2019 - present

Founder, Director, AquaTherapeutic Inc.

2018 - present

Founder, Director, aGUaRx Inc.

2017 - present

Founder, Director, AquaHeart Inc.

2017 - present

Founder, Director, Chief Medical Officer, Attract Medical Inc.

2016 - present

Founder, Director, Chief Medical Officer, Aqua Medical Inc.: 2016

2009 - 2019

Founder, Director, Chief Medical Officer: EndoStim Inc.

2013 - 2016

Founder, Director, Chief Medical Officer: SynerZ Inc.

2010 - present

Founder, Gastroenterologist, Arizona Centers for Digestive Health




Address: 191 W. Second St., Santa Ana, CA 92701, USA

Dieses Feld ist obligatorisch

Dieses Feld ist obligatorisch

Die E-Mail-Adresse ist ungültig

Our services are designed for businesses and their representatives. We do not offer products or services for use by individuals for their personal, family or household purposes. Accordingly, we treat all personal information we collect as pertaining to individuals in their capacities as business representatives and not their individual capacities. We are headquartered in the United States and may use service providers that operate in other countries. Your personal information may be transferred to the United States or other locations where privacy laws may not be as protective as those in your state, province, or country. If you provide us with any sensitive personal information when you use this website, you consent to our processing and use of such personal information to contact you to provide you with more information. If you do not consent to our processing and use of such personal information, you must not submit such personal information through our website. You may withdraw that consent at any time by submitting a request via email to *) Required fields*

Dieses Feld ist obligatorisch

* Kennzeichnet erforderliche Felder
We experienced an error. Please try again
Thank you for your message. We will return to you as soon as possible.